YOYoshitaka Okamoto

Yoshitaka Okamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshitaka Okamoto has a total of 939 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world clinical practice and economic burden of seasonal allergic rhinitis in Japan: A nationwide claims database study

    by Minami Koriyama, Yoshitaka Okamoto, Tomoya Kurokawa, Tatsuya Noda, Yasuyuki Okumura, Daiju Sakurai, Mitsuhiro Okano, Yasushi Suwazono, Tomohisa Iinuma, Toyoyuki Hanazawa, et al.

  • Algorithms in Allergy: Assessment of Rhinitis Using Allergen Exposure Chambers

    by Marek Jutel, Magdalena Zemelka‐Wiacek, Yoshitaka Okamoto, Oliver Pfaar


  • Open Access

    Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan

    by Yoshitaka Okamoto, Moe Kato, Kiyonori Ishii, Yumi Sato, Tomohisa Hata, Yuta Asaka

    Background: Data are limited for clinical outcomes with house dust mite (HDM) allergen immunotherapy beyond 2 years' observation. Materials & methods: A post-marketing drug-use survey assessed the ... Plain language summary The 300 index of reactivity house dust mite (HDM) sublingual tablet (Actair®) is a treatment option for people with HDM allergy. A Japanese study investigated the safety and ... Tweetable abstract Long-term use of the 300 IR HDM tablet is safe and effective.


  • Top Cited Papers
    Open Access

    Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

    by J. Bousquet, E. Melén, T. Haahtela, G. H. Koppelman, A. Togias, R. Valenta, C. A. Akdis, W. Czarlewski, M. Rothenberg, A. Valiulis, et al.

    Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.


  • Open Access

    Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

    by Bernardo Sousa‐Pinto, Aram Anto, Markus Berger, Stephanie Dramburg, Oliver Pfaar, Ludger Klimek, Marek Jutel, Wienczyslawa Czarlewski, Anna Bedbrook, Arunas Valiulis, et al.

    Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real‐time, real‐world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK‐air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.


  • Open Access

    Complement Factor H Is an Early Predictive Biomarker of the Therapeutic Efficacy of Sublingual Immunotherapy for Japanese Cedar Pollinosis

    by Riyo Yoneda, Tomohisa Iinuma, Daiju Sakurai, Junya Kurita, Tomoyuki Arai, Yuri Sonobe, Syuji Yonekura, Yoshitaka Okamoto, Toyoyuki Hanazawa

    Sublingual immunotherapy for Japanese cedar pollinosis can improve the symptoms of allergic rhinitis and modify its natural course. However, sublingual immunotherapy requires a long treatment period and some patients do not respond to treatment. In this study, we aimed to identify biomarkers that could predict the efficacy of sublingual immunotherapy at an early stage. In this study, 40 patients from phase III trials were recruited and divided into good and poor response groups. Using peripheral blood mononuclear cells from before and two months after the start of medication, microarray, discriminant analysis, and real-time polymerase chain reaction were performed to extract candidate genes that could be biomarkers. Furthermore, these genes were validated in 30 patients in general clinical practice. Complement factor H was upregulated in the good response group and downregulated in the poor response group. Complement factor H may be a useful biomarker for predicting the efficacy of sublingual immunotherapy for Japanese cedar pollinosis at early time points after treatment initiation.


  • Open Access

    Increase in eosinophil-derived neurotoxin level in school children with allergic disease

    by Chang-Keun Kim, Dong Yoon Kang, Zak Callaway, Kyoung Soo Kim, Eun Mi Kwon, Fumiya Yamaide, Taiji Nakano, Yoichi Suzuki, Yoichi Mashimo, Akira Hata, et al.

    Background: Eosinophils are major effector cells of allergic disease and excellent markers of eosinophilic inflammation. Accurate and reliable biomarkers are helpful in the diagnosis, treatment, and control of allergic disease. Objective: This study aimed to investigate an alternate marker of eosinophilic inflammation, eosinophil-derived neurotoxin (EDN), in a number of allergic diseases. Methods: Three hundred ninety-six elementary school-age children with various allergic conditions were recruited for this study. Subgroups included food allergies (FAs), atopic dermatitis (AD), bronchial asthma (BA), and allergic rhinitis (AR). EDN levels in these groups were compared to those in 93 healthy controls (HC). Results: All subjects with allergic disease had elevated levels of serum EDN (median [interquartile range]: FA, 124.2 ng/mL [59.13-160.5 ng/mL]; AD, 110.8 ng/mL [57.52-167.9 ng/mL]; BA, 131.5 ng/mL [60.60-171.0 ng/mL]; AR, 91.32 ng/mL [46.16-145.0 ng/mL]) compared to HC (38.38 ng/mL [32.40-55.62 ng/mL]) (p < 0.0001). These elevated levels were consistent throughout the age range (6-12 years) of the healthy study subjects (p = 0.0679). EDN levels also correlated well with total immunoglobulin E (Rs = 0.5599, p < 0.0001). Looking at all individuals with an allergic disease, the area under the curve was 0.790. Conclusions: Direct measures of eosinophilic inflammation are needed for accurate diagnosis, treatment, and monitoring of allergic diseases. EDN may be a worthy biomarker of eosinophil activity and a useful screening tool for allergic diseases including FA, AD, BA, and AR.


  • Open Access

    Evaluation of shoseiryuto for seasonal allergic rhinitis, using an environmental challenge chamber

    by Junya Kurita, Syuji Yonekura, Tomohisa Iinuma, Riyo Yoneda, Sakiko Imamoto, Toyoyuki Hanazawa, Yohei Kawasaki, Takao Namiki, Yoshitaka Okamoto


  • Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air

    by Bernardo Sousa-Pinto, Ana Sá-Sousa, Rita Amaral, Wienczyslawa Czarlewski, Anna Bedbrook, Josep M. Anto, Jean Bousquet, João Almeida Fonseca, I. Agache, X. Basagaña, et al.


  • Open Access

    Safety and Effectiveness of the 300 IR Sublingual House Dust Mite Allergen Immunotherapy Tablet: 2-Year Interim Analysis of a Specified Drug-Use Survey

    by Yoshitaka Okamoto, Kiyonori Ishii, Moe Kato, Haruna Hayashi, Tomohisa Hata

    Background: The efficacy and safety of a house dust mite sublingual tablet (HDM-tab) have been demonstrated in clinical trials, but the findings must be confirmed in real-world use among more wides...